newsfilter
← Latest News
GlobeNewswire·

Celldex Reports Third Quarter Financial Results and Provides Corporate Update

Best-in-disease results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies showed rapid, profound, sustained efficacy supporting barzolvolimab’s potential to be a transformational therapy in CSUBLA submission for